Top Markets
#1 WYDE: End Hunger WYDE: End Hunger +2.71%
#2 MetaDAO MetaDAO +2.37%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +2.27%
#4 PulseX PulseX +1.94%
#5 The Grays Currency The Grays Currency +1.93%
#6 Dual Dual +1.86%
#7 Wrapped Pulse Wrapped Pulse +1.56%
#8 Anvil Anvil +1.50%
#9 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +1.49%
#10 Bitway Bitway +1.33%
Coin of the day
WYDE: End Hunger WYDE: End Hunger
Innstillinger
Språk
NORSK
Valuta
USD
Tema
CG Oncology Inc. CG Oncology Inc.

CG Oncology Inc.

CGON
Rangering i aksjer #2843
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops... CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Aksjekurs
$78.86
Sist synkronisert: 2026-08-25
Markedsverdi
$6.96B
Endring (1 dag)
0.80%
Endring (1 år)
191.75%
Land
US
Handel CG Oncology Inc. (CGON)

Kategori

Healthcare
EPS for CG Oncology Inc. (CGON)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til CG Oncology Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for CG Oncology Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH